概括
班佩多酸显著减少了对他类药物不耐受患者的心血管事件. 这一发现为无法耐受胆固醇管理他类药物的人提供了新的治疗选择.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 斯坦丁不耐受性影响了很大一部分需要降脂治疗的患者.
- 对于无法耐受他类药物的患者,需要使用替代性降脂剂.
- 降低心血管风险仍然是管理高脂血症的主要目标.
研究的目的:
- 评估bempedoic酸在降低对他类药物不耐受患者心血管结果方面的疗效和安全性.
- 评估bempedoic酸作为他类药物的替代品在初级和二级心血管预防中的作用.
主要方法:
- 进行了一项大规模的,随机的,双盲的,安慰剂控制的试验 (SELECT-CHOICE).
- 参与者是对他类药物不耐受,患有已确定的动脉样硬化心血管疾病或高心血管风险的患者.
- 根据指示,患者除了接受其他降脂疗法外,还接受了bempedoic酸或安慰剂.
主要成果:
- 班佩多酸在主要不良心血管事件 (MACE) 的复合终点上显示出统计学上显著的减少.
- 与安慰剂相比,bempedoic acid组中心血管死亡,非致命的心肌梗塞和非致命中风的发生率较低.
- 组间的不良事件概况在总体上是相似的,在肌肉相关的副作用方面有显著的例外.
结论:
- 班佩多酸是降低他类药物不耐受患者心血管风险的有效选择.
- 该药物为那些无法通过他类药物实现脂质目标的患者提供了有价值的治疗替代品.
- 进一步的研究可能会探索长期结果和更广泛的患者群体.
相关概念视频
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
497
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
497
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
869
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
869
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
540
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
540
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K